Paul Tudor Jones Adaptimmune Therapeutics PLC Transaction History

Tudor Investment Corp Et Al

  • $26.8 Billion
  • Q3 2024

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2022

May 16, 2022
SELL
$1.73 - $4.06 $1,159 - $2,720
-670 Reduced 4.21%
15,232 $31,000
Q4 2021

Feb 14, 2022
SELL
$3.5 - $5.68 $357 - $579
-102 Reduced 0.64%
15,902 $60,000
Q3 2021

Nov 15, 2021
BUY
$3.44 - $6.37 $55,053 - $101,945
16,004 New
16,004 $83,000

Others Institutions Holding ADAP

# of Institutions
83
Shares Held
145M
Call Options Held
60.8K
Put Options Held
5.8K
View Full List

About Adaptimmune Therapeutics PLC

ADAP Quotes by TradingView
  • Ticker ADAP
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 163,370,000
  • Market Cap $99.7M
  • Description
  • Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on providing novel cell therapies primarily to patients with solid tumors in the United States and the United Kingdom. The company's specific peptide enhanced affinity receptor (SPEAR) T-cell platform enables it to identify cancer targets. It is developing ADP-A2M4...
More about ADAP
Track Paul Tudor Jones's Portfolio

Track Paul Tudor Jones Portfolio

Follow Paul Tudor Jones (Tudor Investment Corp Et Al) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Tudor Investment Corp Et Al, based on Form 13F filings with the SEC.

News

Stay updated on Tudor Investment Corp Et Al and Paul Tudor Jones with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email